RemeGen Co., Ltd. (9995.HK)
| Previous close | 30.000 |
| Open | 30.900 |
| Bid | 30.250 x N/A |
| Ask | 30.450 x N/A |
| Day's range | 29.550 - 30.900 |
| 52-week range | 14.960 - 50.300 |
| Volume | |
| Avg. volume | 2,269,480 |
| Market cap | 28.131B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.020 |
| Earnings date | 27 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 44.90 |
PR NewswireRemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, obtained Fast Track Designation (FTD) by the United States Food and Drug Administration (FDA) recently for its innovative BLyS/APRIL dual-target fusion protein drug, Telitacicept (RC18), independently developed by RemeGen for the treatment of patients with primary Sjögren's syndrome (pSS). The FDA grants FTD to accelerate the development and review of new drugs that have the potential to
PR NewswireRemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the Company's proprietary Disitamab Vedotin (RC48), an investigational anti-HER2 antibody-drug conjugate (ADC) targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology (ESGO 2024 Congress) held in Barcelona from March 7-10, 2024.
PR NewswireWorld Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments. The Company not only endeavors to contribute to the field of anti-cancer treatments, but also provide much-improved medical opportunitie
